BackgroundA urinary tract infection (UTI) is a common medical condition complicating pregnancy with adverse maternal and perinatal outcomes. This study aimed to assess any adverse maternal and perinatal morbidity related to UTI in pregnancy, focusing on identifying common uropathogens and their antibiotic sensitivity and resistance patterns. MethodsWe conducted a retrospective cohort study at Corniche Hospital, Abu Dhabi. The study population consisted of 549 women in the exposed group (i.e., those with at least one episode of UTI in pregnancy in 2018) and 329 in the comparison group (i.e., those without UTI). Statistical analysis was done using SPSS Statistics for Windows, Version 19.0 (SPSS Inc., Chicago, IL). The study's primary outcome measures were preterm birth, recurrent UTI, pyelonephritis, and low birth weight (LBW). ResultsWomen who had a UTI during pregnancy had more preterm deliveries than those without a UTI (c2=7.092; p=0.007). Recurrent UTI was observed in 26.6% of women with UTI, while the incidence of pyelonephritis was relatively low in this group (1.45%). There was no significant association between LBW and UTI in pregnancy (c 2 =0.097; p=0.756). The most common bacteria isolated from women with UTI were Group B Streptococcus (GBS, 31.3%), followed by Escherichia coli (30.9%). They were sensitive to a wide range of antibiotics. ConclusionAccording to our results, significant predictors of bacteriuria in pregnancy history include UTI, renal calculi, and nulliparity. Women with UTI in pregnancy are more likely to have preterm delivery. However, adequate management can minimize other complications like pyelonephritis and adverse perinatal outcomes. Available evidence prompts the recommendation of routine screening for asymptomatic bacteriuria (ASB) in early pregnancy to minimize complications and identify those women at significant risk for preterm delivery.

No abstract

Objective: The study was conducted with an objective to achieve a potential sustained release oral drug delivery system of an antihypertensive drug, perindopril which is a angiotensin converting enzyme inhibitor having half-life of 2 hrs. Perindopril is water-soluble drug, so we can control or delay the release rate of drug using release retarding polymers. This may also decrease the toxic side effects by preventing the high initial concentration in the blood.Methods: Microcapsules were prepared by solvent evaporation technique using Eudragit L100 and ethyl cellulose as a retarding agent to control the release rate and magnesium stearate as an inert dispersing carrier to decrease the interfacial tension between lipophilic and hydrophilic phase.Results: Prepared microcapsules were evaluated for the particle size, percentage yield, drug entrapment efficiency, flow property, and in vitro drug release for 12 hrs. Results indicated that the percentage yield, mean particle size, drug entrapment efficiency, and the micrometric properties of the microcapsules were influenced by various drug:polymer ratio. The release rate of microcapsules could be controlled as desired by adjusting the combination ratio of dispersing agents to retarding agents. Conclusion:Perindopril microcapsules can be successfully designed to develop sustained drug delivery that reduces the dosing frequency and their by one can increase the patient compliance.